Immunoregulatory T Cell Function in Multiple Myeloma
Overview
Authors
Affiliations
Multiple myeloma is a malignancy characterized by uncontrolled monoclonal B cell differentiation and immunoglobulin production. In most instances, there is concomitant reduction in polyclonal differentiation and immunoglobulin synthesis both in vivo and in vitro. In in vitro pokeweed mitogen-induced B cell differentiation assays, proliferation and polyclonal immunoglobulin secretion optimally requires T cell help and can be inhibited both by monocytes and suppressor T cells. Helper function and monocyte-mediated suppression are relatively radio-resistant whereas T suppressor function is sensitive to 2,000 rad x-irradiation. We have examined myeloma T cell subset function in this assay using recombinations of isolated patient and normal B cells, T cells, and T cell subsets. Monocytes were removed by a carbonyl iron ingestion technique, normal and myeloma T cells were fractionated on the basis of Fc receptors for immunoglobulin (Ig) G (Tgamma) or IgM (Tmu or T non-gamma), and proliferation and IgG secretion after co-culture determined by [(3)H]thymidine incorporation and radio-immunoassay, respectively. Myeloma B cells demonstrate quantitatively and qualitatively normal blastogenic responses and are appropriately regulated by either autologous or allogeneic T helper and suppressor subsets. Despite normal proliferation, however, myeloma B cells remain deficient in subsequent differentiation and immunoglobulin secretion even when co-cultured in the absence of monocytes or suppressor T cells and the presence of normal helper cells. Myeloma T cell populations, in contrast, are entirely normal in helper capacity over a range of T:B ratios but are markedly deficient in radiosensitive and concanavalin A-induced suppressor activity. T suppressor cell dysfunction in multiple myeloma is apparently due to a deficit in the T non-gamma suppressor subset, whereas Tgamma cells, although proportionately reduced, are functionally normal. This unique T suppressor deficit reflects the heterogeneity of suppressor mechanisms in this disease and may represent a compensatory response to the monoclonal proliferation or the involvement of regulatory T cells in the pathogenesis of the malignancy.
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges.
Rendo M, Joseph J, Phan L, DeStefano C Blood Lymphat Cancer. 2022; 12:119-136.
PMID: 36060553 PMC: 9439649. DOI: 10.2147/BLCTT.S327016.
Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A Leukemia. 2014; 28(10):2075-9.
PMID: 24637336 DOI: 10.1038/leu.2014.110.
Berthaud V, Milder J, El-Sadr W J Natl Med Assoc. 1993; 85(8):626-8.
PMID: 8371286 PMC: 2568107.
Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.
Hoover R, Lary C, Page R, Travis P, Owens R, Flick J J Clin Invest. 1995; 95(1):241-7.
PMID: 7529259 PMC: 295416. DOI: 10.1172/JCI117646.
Dammacco F, Miglietta A, Ventura M, BONOMO L Clin Exp Immunol. 1982; 47(2):481-6.
PMID: 7075030 PMC: 1536528.